The Travel Vaccines Market is Growing Rapidly and is Projected to Reach $6.46 Billion by 2030

The Travel Vaccines Market

Travel Vaccines Market Report

Travel Vaccines Market Analysis

The Business Research Company’s The Travel Vaccines Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, October 27, 2026 /EINPresswire.com/ -- The growing trend of international travel has significantly influenced the demand for specialized health precautions, particularly in the area of travel vaccines. As more people venture beyond their home countries for leisure, business, or education, the need for effective immunization against region-specific diseases is becoming increasingly important. This overview explores the size, growth, regional dynamics, key market drivers, and leading companies shaping the travel vaccines market.

Travel Vaccines Market Size and Relationship to Broader Pharmaceutical Industry
The travel vaccines market is projected to exceed $6 billion by 2030. When compared to the broader preventive vaccines market, which is expected to reach roughly $131 billion by the same year, travel vaccines will account for approximately 5% of that parent sector. Within the vast pharmaceuticals industry—anticipated to be valued at about $2,496 billion by 2030—the travel vaccines segment will represent close to 0.3% of the overall market value.

Request A Free Sample Of The Travel Vaccines Market Report
https://thebusinessresearchcompany.com/sample_request?id=70152883&type=smp&name=Travel%20Vaccines%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

North America’s Dominance in the Travel Vaccines Market by 2030
In 2030, North America is set to be the leading region for the travel vaccines market, with an estimated value of $2.1 billion. This represents growth from $1.5 billion in 2025, at a steady compound annual growth rate (CAGR) of 7%. Several factors contribute to this surge, including increasing international travel and outbound tourism from the United States and Canada, heightened awareness of travel-related infectious diseases, and expanded access to vaccination through airport clinics and retail outlets. Additionally, growing corporate health initiatives, occupational immunization programs, digital health platforms improving vaccine accessibility, and robust public health campaigns encouraging immunization compliance among travelers all support this regional growth.

The United States as the Largest Country Market for Travel Vaccines in 2030
The USA is forecasted to be the single largest country market within travel vaccines by 2030, with sales reaching $1.9 billion, growing from $1.4 billion in 2025 at a CAGR of 6%. The country’s growth is driven by rising outbound travel for leisure, education, and business, coupled with increasing adoption of preventive healthcare among international travelers. Expansion of private travel clinics, pharmacy-based vaccination services, employer-supported health programs, improved insurance coverage for travel vaccines, and integration of travel health consultations into primary care and telehealth services are also key contributors.

Access The Detailed Travel Vaccines Market Report Here
https://thebusinessresearchcompany.com/report/travel-vaccines-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

Disease Segments Within the Travel Vaccines Market and Hepatitis A’s Leading Role
The travel vaccines market is categorized by disease into segments such as hepatitis A, diphtheria, pertussis, and tetanus (DPT), yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, and others. Among these, hepatitis A is expected to be the largest segment, making up 25% of the market and valued at $2 billion in 2030. This segment benefits from increased exposure risks faced by travelers through contaminated food and water, especially in tropical and emerging destinations. The growing endorsement of hepatitis A vaccination in pre-travel consultations, stronger recommendations by global health authorities, and steady demand from military, humanitarian workers, and expatriates further support this segment.

Other Market Segmentation Criteria for Travel Vaccines
Beyond disease type, the travel vaccines market is segmented by composition into mono vaccines and combination vaccines. It is also divided based on booking channels, which include online booking and in-person booking. Furthermore, application-wise segmentation separates the market into domestic travel and outbound travel categories.

Expected Growth Rate of the Travel Vaccines Market Through 2030
The travel vaccines market is poised for a compound annual growth rate of 7% up to 2030, signaling strong and sustained expansion driven by global travel trends and health awareness.

Factors Encouraging Growth in the Global Travel Vaccines Market
The overall rapid expansion of the travel vaccines market is being fueled by several key elements that stimulate international travel and awareness of infectious disease prevention. One major contributor is the increasing volume of outbound tourism, which exposes individuals to regions with elevated infection risks such as yellow fever, hepatitis, typhoid, and rabies. The rise in leisure, business, educational, and adventure travel has heightened the focus on preventive healthcare and compliance with vaccination mandates set by destination countries. This enhanced global connectivity and post-pandemic travel recovery are sharpening the demand for travel vaccines worldwide, pushing an estimated annual market growth of 2.7%.

Impact of Hepatitis A Prevalence in Popular Travel Destinations
Hepatitis A remains widespread across many popular international destinations, particularly in regions with poor sanitation and contaminated resources such as parts of Asia, Africa, Latin America, and the Middle East. This widespread prevalence is a critical driver for the travel vaccines segment targeting hepatitis A. As more travelers become aware of the risks and as authoritative health bodies like the CDC and WHO strongly recommend vaccination, demand for hepatitis A immunization rises steadily. The increasing movement of tourists, business travelers, students, and adventure seekers to endemic areas further accelerates this trend, contributing an estimated 2.5% annual growth to the market.

Influence of Business Travel and Global Events on Travel Vaccines Demand
The growth of meetings, incentives, conferences, and exhibitions (MICE) activities worldwide plays an important role in driving demand for travel vaccines. Expanding international business travel linked to corporate events, trade shows, and incentive trips is pushing more travelers to countries with vaccine requirements. Recovery and expansion of the global events sector, alongside increased cross-border business mobility, are heightening the need for preventive immunization and travel health services. This factor is expected to add around 2.2% to the annual growth rate of the travel vaccines market.

Key Growth Prospects in Specific Travel Vaccines by 2030
Significant opportunities in the travel vaccines market lie across several disease-specific segments, including hepatitis A, diphtheria, pertussis, and tetanus (DPT), yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal disease, and various other infections. Collectively, these categories are projected to add more than $2.4 billion in market value by 2030. This growth is supported by factors such as increased cross-border travel for tourism, education, and relocation; stricter destination-specific immunization requirements tied to immigration rules; heightened traveler awareness of infectious disease prevention; expansion of private healthcare travel advisory services; and greater integration of vaccination consultations with digital health platforms. These trends highlight a broader focus on preventive travel health, enhanced global travel safety, and widespread adoption of targeted immunization strategies, fueling transformative growth in the travel vaccines sector.

Projected Value Increases for Major Disease Segments by 2030
Between 2025 and 2030, the hepatitis A vaccine segment is expected to grow by $1 billion. Meanwhile, the diphtheria, pertussis, and tetanus (DPT) segment will increase by $0.3 billion, yellow fever and typhoid will each rise by $0.2 billion, hepatitis B will also expand by $0.2 billion, measles and mumps by $0.1 billion, rabies by $0.1 billion, meningococcal vaccines by $0.1 billion, and other disease categories by $0.2 billion. This steady expansion reflects diversified demand across multiple preventive immunization areas related to travel.

Market Composition and Competitive Dynamics in Travel Vaccines
The travel vaccines market consists of a blend of global vaccine manufacturers alongside pharmaceutical companies focused on public health. Industry players are investing in advanced vaccine technologies, including combination vaccines and rapid development platforms, alongside improvements in cold-chain logistics to ensure broad immunization availability for travelers. Key competitive factors include growing international travel, region-specific disease risks, and adherence to stringent regulatory and vaccination guidelines. To capitalize on market growth, companies are emphasizing innovation, strategic partnerships, and geographic expansion within the travel health ecosystem.

Leading Company in the Travel Vaccines Market and Market Share
Sanofi S.A. emerged as the market leader in 2025, holding a 5% share of global sales in travel vaccines. The company’s vaccines division offers a broad portfolio of immunization products, including travel-specific vaccines, combination formulations, and preventive biologics targeted at protection against infectious diseases that pose risks to international travelers.

Key Players Shaping the Travel Vaccines Industry
Besides Sanofi S.A., major participants in the travel vaccines field include GlaxoSmithKline (GSK plc), Pfizer Inc., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Bavarian Nordic A/S, CSL Limited, Serum Institute of India Pvt. Ltd., Valneva SE, Bharat Biotech International Limited, SK Bioscience Co., Ltd., Indian Immunologicals Ltd., LG Chem Life Sciences, Meiji Holdings Co., Ltd., Kangtai Biological Products, Panacea Biotec, Biological E. Limited, Shanghai Institute of Biological Products Co., Ltd., Vabiotech, Zydus Lifesciences Ltd., and Bio Farma.

Market Concentration and Industry Structure
The travel vaccines market is moderately fragmented, with the top 10 companies accounting for 22% of total revenue in 2025. This moderate concentration reflects the complex regulatory environment, rigorous vaccine safety standards, challenging clinical development processes, and cold-chain distribution requirements. Leading companies maintain strong market positions through diverse vaccine portfolios, robust research and development, regulatory approvals, global manufacturing capabilities, and ongoing innovation in preventive immunization. As demand grows driven by international travel and health regulations, strategic collaborations and geographic outreach will be crucial for sustained competitiveness.

Primary Raw Material Suppliers Supporting the Travel Vaccines Market
Key suppliers of raw materials for travel vaccines include industry giants such as GlaxoSmithKline plc, Sanofi S.A., Pfizer Inc., Merck and Co. Inc., Johnson and Johnson, AstraZeneca plc, Moderna Inc., Bavarian Nordic A/S, Bharat Biotech International Limited, Serum Institute of India Private Limited, Sinovac Biotech Ltd., Sinopharm Group Co. Ltd., Takeda Pharmaceutical Company Limited, Novavax Inc., Abbott Laboratories, Boehringer Ingelheim International GmbH, CSL Limited, Emergent BioSolutions Inc., Daiichi Sankyo Company Limited, Hualan Biological Engineering Inc., Changchun Changsheng Life Sciences Limited, SK Bioscience Co. Ltd., Medigen Vaccine Biologics Corporation, BioNTech SE, and Zhejiang Walvax Biotechnology Co. Ltd.

Key Wholesalers and Distributors in the Travel Vaccines Market
The market’s distribution network includes major wholesalers and distributors such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health Inc., Henry Schein Inc., Owens and Minor Inc., Medline Industries LP, Movianto GmbH, Uniphar Group plc, Phoenix Pharmahandel GmbH and Co KG, Alliance Healthcare Group, Zuellig Pharma Holdings Pte. Ltd., Sinopharm International Corporation, Shanghai Pharma Group Co. Ltd., H. D. Smith LLC, Morris and Dickson Co. LLC, Anda Inc., CuraScript SD, Onco360 Specialty Pharmacy, Walgreens Boots Alliance Distribution, CVS Health Corporation Distribution Services, Rite Aid Corporation Distribution Network, Boots UK Limited Distribution Services, Walgreens Specialty Pharmacy, Medipal Holdings Corporation, and Alfresa Holdings Corporation.

Major End Users Benefiting from Travel Vaccines
Prominent end users of travel vaccines include international and national public health organizations such as the World Health Organization, Centers for Disease Control and Prevention, National Health Service UK, Ministry of Health and Family Welfare India, European Centre for Disease Prevention and Control, Pan American Health Organization, and UNICEF. Other key users include Médecins Sans Frontières, International SOS, Travel Health Clinics of America, Mayo Clinic Travel Medicine Center, Cleveland Clinic Travel Medicine Services, Johns Hopkins Travel Medicine Clinic, Apollo Hospitals Travel Health Services, Fortis Healthcare Travel Clinic, Max Healthcare Travel Medicine Unit, Singapore General Hospital Travel Clinic, National University Hospital Singapore, Bangkok Hospital Travel Clinic, Bumrungrad International Hospital Travel Medicine Center, PathCare Travel Health Services, Blue Cross Blue Shield Health Travel Programs, Kaiser Permanente Travel Medicine Services, United States Army Public Health Command, and the Australian Department of Health Travel Advisory Services.

Competitive Trends Reshaping the Travel Vaccines Market
Advancements in travel immunization vaccines are revolutionizing preventive healthcare for travelers by offering active protection against region-specific diseases. For example, in January 2024, Indian Immunologicals Ltd. launched Havisure, India’s first domestically developed hepatitis A vaccine designed for travelers and at-risk groups. This vaccine helps prevent hepatitis A infection, supports routine immunization programs, and contributes to reducing liver complications in high-risk regions.

Strategic Approaches Adopted by Travel Vaccine Companies
To maintain competitive advantage, companies are focusing on several key strategies: enhancing vaccine research and development to improve protection and global health security; utilizing novel vaccine platforms that enable rapid response and prevention; expanding cold chain infrastructure to improve accessibility and worldwide coverage; and implementing travel vaccine decision support systems to better predict outbreaks and assist healthcare providers in making informed immunization choices.

New additions to our 2026 reports:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 30,000+ reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: marketing@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X